Estados financieros detallados de Lantern Pharma Inc. (LTRN): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.93, LTRN presenta beneficios negativos (P/E no significativo) y un ROE del -456.35%. La capitalización bursátil es de $25M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | -$2544 | $1627 | 0 | 0 | 0 | $174843 | 0 | 0 |
| Beneficio Bruto | $2544 | -$1627 | 0 | 0 | 0 | -$174843 | 0 | 0 |
| I+D | $572095 | $953185 | $2.2M | $7.6M | $8.60B | $11.9M | $16.1M | $11.5M |
| Generales y Administrativos | $1.2M | $1.5M | $3.7M | $5.0M | $5.83B | $6.0M | $6.1M | $6.5M |
| Gastos Operativos | $1.7M | $2.4M | $5.9M | $12.6M | $14.43B | $17.7M | $22.2M | $18.0M |
| Beneficio Operativo | -$1.7M | -$2.4M | -$5.9M | -$12.6M | -$14.43B | -$17.9M | -$22.2M | -$18.0M |
| EBITDA | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$15.8M | -$20.8M | -$17.1M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$16.0M | -$20.8M | -$17.1M |
| Impuestos | $2544 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.26B | -$16.0M | -$20.8M | -$17.1M |
| BPA | $-0.28 | $-0.39 | $-0.95 | $-1.13 | $-1.31 | $-1.47 | $-1930.92 | $-1.57 |
| BPA Diluido | $-0.28 | $-0.39 | $-0.95 | $-1.13 | $-1.31 | $-1.47 | $-1930.92 | $-1.57 |
| Acciones en Circulación (Diluidas) | $6.2M | $6.3M | $6.2M | $10.9M | $10.9M | $10.8M | $10.8M | $10.9M |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $445163 | $1.2M | $19.2M | $51.5M | $37.2M | $21.9M | $7.5M | $4.4M |
| Inversiones a Corto | 0 | 0 | 0 | $19.2M | $18.0M | $19.4M | $16.5M | $5.7M |
| Cuentas por Cobrar | 0 | 0 | 0 | $181000 | 0 | $860000 | 0 | $30000 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $445163 | $1.2M | $20.2M | $72.7M | $58.7M | $43.3M | $25.2M | $10.8M |
| Inmovilizado Material | $4668 | $8758 | $21507 | $216188 | $95695 | $280422 | $287425 | $107.5M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $449831 | $1.4M | $20.4M | $74.0M | $58.8M | $43.6M | $25.6M | $11.0M |
| Cuentas por Pagar | $97629 | $478292 | $432339 | $2.2M | 0 | $942211 | 0 | $4.4M |
| Deuda a Corto | 0 | 0 | 0 | $152058 | 0 | 0 | 0 | $78.5M |
| Pasivos Corrientes | $651629 | $489292 | $552339 | $2.3M | $2.8M | $2.7M | $4.3M | $4.5M |
| Deuda a Largo | 0 | 0 | $108500 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $651629 | $489292 | $660839 | $2.4M | $2.8M | $2.7M | $4.4M | $4.5M |
| Reservas | -$4.3M | -$6.8M | -$12.7M | -$25.0M | -$39.3M | -$55.2M | -$76.0M | -$93.1M |
| Patrimonio Neto | -$201798 | $943284 | $19.7M | $71.6M | $56.0M | $40.9M | $21.2M | $6.5M |
| Deuda Total | 0 | 0 | $108500 | $204948 | $52890 | $234471 | $243657 | $78.5M |
| Deuda Neta | -$445163 | -$1.2M | -$19.1M | -$70.5M | -$55.1M | -$41.1M | -$23.8M | $68.4M |
| Capital Circulante | -$206466 | $743526 | $19.7M | $70.4M | $55.9M | $40.7M | $20.9M | $6.3M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$1.7M | -$2.4M | -$5.9M | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Amortizaciones | -$2544 | $1627 | $3388 | $6761 | $10081 | $14615 | $17282 | $17280 |
| Compensación en Acciones | $185604 | $117760 | $1.2M | $961545 | $1.2M | $1.1M | $732893 | $650877 |
| Cambio en Capital Circulante | $271840 | $180875 | -$939060 | $599957 | -$611863 | $538024 | $2.2M | $635278 |
| Flujo de Caja Operativo | -$1.3M | -$2.1M | -$5.7M | -$10.6M | -$12.8M | -$14.3M | -$17.8M | -$15.7M |
| Inversiones (CapEx) | 0 | -$5717 | -$16137 | -$15499 | -$27844 | -$18734 | -$12595 | -$1715 |
| Adquisiciones | $5337 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | -$2.5M | -$499997 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.3M | -$2.1M | -$5.7M | -$10.6M | -$12.8M | -$14.4M | -$17.8M | -$15.7M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -40.6% | -143.3% | -109.3% | -115243.5% | +99.9% | -30.2% | +17.6% | |
| Crecimiento BPA (anual) | -39.3% | -143.6% | -18.9% | -15.9% | -12.2% | -131255.1% | +99.9% | |
| Cambio en Acciones (anual) | +0.8% | -0.7% | +75.3% | -0.5% | -0.1% | -0.7% | +1.3% | |
| Crecimiento FCF (anual) | -67.8% | -165.6% | -87.1% | -20.6% | -12.3% | -24.1% | +12.0% | |
| Tasa Impositiva Efectiva | -0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.20 | $-0.34 | $-0.91 | $-0.97 | $-1.18 | $-1.32 | $-1.66 | $-1.44 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $6.2M | $6.3M | $6.2M | $10.9M | $10.9M | $10.8M | $10.8M | $10.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -456.35% |
| Rentabilidad sobre capital invertido | -358.04% |
| Rentabilidad sobre activos | -216.84% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | -0.01 |
| Ratio corriente | 1.96 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -53.39 | -38.33 | -20.26 | -7.06 | -4.61 | -2.91 | -0.00 | -1.93 |
| P/VC | -460.62 | 99.29 | 6.08 | 1.22 | 1.17 | 1.13 | 1.62 | 5.05 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ANVS · ATNM · BCAB · CALC · ELUT · LVTX · MAIA
Explorar sector: Healthcare · Biotechnology
Más secciones de LTRN: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones